GI Signals · Trends

The digest, over time.

Charts from the 8 published issues so far: how selective it stays, which areas are busy, and what moves the standard of care.

01 / OVER TIME

How selective it stays

Papers surfaced as a share of papers screened, each week (oldest first). It should stay low and steady.

0%10%20%30%40%Surfaced %7%06/24/269%07/12/2616%07/19/2637%07/26/2631%08/02/2634%08/09/2628%08/16/2629%08/23/26
02 / OVER TIME

Which areas are busy

Surfaced papers by subspecialty, week by week (oldest at left). A busy section or a quiet stretch shows up week to week.

06/24/26
07/12/26
07/19/26
07/26/26
08/02/26
08/09/26
08/16/26
08/23/26
IBD
5
1
5
6
19
9
5
11
Hepatology
2
5
4
12
36
14
9
6
Esophagus/Reflux
2
2
2
4
5
1
Pancreas/Biliary
3
2
5
2
11
5
3
6
Endoscopy
5
5
4
21
18
16
8
8
Motility
4
5
7
9
3
3
5
Colorectal
5
2
1
3
9
5
2
Nutrition
3
2
3
2
03 / OVER TIME

How much each week shifts the standard

Mean standard-shift by week, oldest first (1 reinforces current practice, 5 challenges it). A busy week reads differently from a quiet one.

12345Mean shift3.306/24/262.107/12/262.607/19/261.907/26/261.508/02/262.108/09/262.108/16/262.308/23/26
04 / OVER TIME

Which journals show up most

Cumulative surfaced papers by journal: the journals that carry the signal, week after week.

Inflamm Bowel Dis34
Dig Dis Sci22
J Gastro Hep19
J Neurogastro Motil19
GIE19
Liver International19
Endoscopy17
Clin Gastro Hep16
05 / OVER TIME

The run so far

One tile per week (oldest first): how many papers surfaced and the spread of their signal scores.

06/24/26 · #1
29surfaced
score 7 to 92
07/12/26 · #2
17surfaced
score 32 to 80
07/19/26 · #3
28surfaced
score 37 to 83
07/26/26 · #4
58surfaced
score 32 to 80
08/02/26 · #5
107surfaced
score 35 to 87
08/09/26 · #6
52surfaced
score 32 to 79
08/16/26 · #7
28surfaced
score 16 to 79
08/23/26 · #8
41surfaced
score 40 to 88
06 / THIS ISSUE

The signal map

Every surfaced paper placed by study rigor and novelty; dot size is journal standing. Top right is the week's must-read.

EmergingReinforcesRefinesChangesstrong evidence · moves the standardnarrative reviewguideline →How far it moves the standardEvidence strength
07 / THIS ISSUE

What drove each score

The top papers, each split into the four scoring parts, so you can see why a paper ranked without opening its card.

AI-assisted second forward-view examination of the right colon significantly improves the adenoma detection rate: a multicenter randomized controlled trial.88
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.85
Standardized Assessment of Complete Colorectal Polyp Resection for Polyps <20 mm (SCOPE): a Delphi Consensus.85
Effectiveness of theory-based WhatsApp chatbot outreach in colorectal cancer screening uptake: a randomized controlled trial.84
Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.76
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.76
Aminosalicylate use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease.76
Consolidation Therapy of Probiotics With Rifaximin Prevent Relapse in Rifaximin-Responsive Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Randomized Clinical Trial.68
Clinical and endoscopic features of checkpoint inhibitor-induced colitis and their association with selective immunosuppressive therapy use.71
Hormonal contraception is not associated with recurrent flares in ulcerative colitis: a longitudinal time-dependent analysis.67
ROTEM-guided blood product transfusion in patients with cirrhosis having invasive procedures: a randomized controlled trial.65
Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification.62
Study rigorShiftPractice relevanceJournal standing